Can I Take Reishi Mushroom With Losartan? A Women's Health Guide to This Supplement Interaction

What Is Losartan and Why Do Women Take It?

Losartan is an angiotensin II receptor blocker (ARB) prescribed most often for hypertension, heart failure, and diabetic nephropathy. For women specifically, losartan also appears in clinical practice for three additional reasons: reducing proteinuria in women with type 2 diabetes and kidney disease, managing hypertension in postmenopausal women whose cardiovascular risk rises sharply after estrogen decline, and off-label management of hypertension in women with polycystic ovary syndrome (PCOS) who have concurrent insulin resistance.

How Losartan Works in the Female Body

Losartan is a prodrug. After you swallow it, your liver converts roughly 14 percent of the dose into an active acid metabolite called E-3174 via the enzyme CYP2C9. E-3174 is 10 to 40 times more potent than losartan itself as an ARB. This conversion step is the critical pharmacokinetic detail that makes the reishi interaction biologically plausible.

Women metabolize drugs differently than men in ways that matter here. Estrogen and progesterone modulate CYP enzyme activity across the menstrual cycle. A 2016 review in Clinical Pharmacokinetics confirmed that CYP2C9 activity is measurably lower during the luteal phase in reproductive-age women compared with men or postmenopausal women. Lower baseline CYP2C9 activity means any additional inhibitor, including reishi, could have a proportionally larger effect on E-3174 formation in premenopausal women.

Life-Stage Differences in Who Takes Losartan

Reproductive years. Hypertension in women under 40 is less common but occurs in PCOS, lupus nephritis, and renovascular disease. Losartan is occasionally used but must be stopped before conception (see pregnancy section below).

Perimenopause. Blood pressure tends to rise in perimenopause partly because of vasomotor instability and partly because declining estrogen reduces nitric-oxide-mediated vasodilation. Women in this stage are increasingly likely to be started on an ARB.

Postmenopause. This is the peak demographic for losartan in women. The LIFE trial showed losartan reduced the primary composite endpoint of cardiovascular death, stroke, and myocardial infarction by 13 percent compared with atenolol in hypertensive patients with left ventricular hypertrophy, with women making up 46 percent of the 9,193 participants enrolled.

What Is Reishi Mushroom and Why Are Women Taking It?

Reishi (Ganoderma lucidum) is one of the most widely purchased medicinal mushrooms in the United States. Women reach for it most often as a stress adaptogen, an immune modulator, and, increasingly, for sleep support during perimenopause. Sales of reishi-containing supplements in the U.S. Have grown significantly, and it frequently shows up in "menopause support" blends alongside ashwagandha, black cohosh, and magnesium.

The Active Compounds That Create Interaction Risk

Reishi contains three pharmacologically active compound classes relevant to this interaction:

• Triterpenoids (ganoderic acids). These are the compounds most studied for CYP enzyme effects. In vitro data published in Drug Metabolism and Disposition showed that ganoderic acid A and ganoderic acid H inhibited CYP2C9 activity in human liver microsomes. The clinical significance of in-vitro inhibition does not always translate cleanly to whole-body drug levels, but the signal is specific enough to warrant attention.
• Polysaccharides (beta-glucans). These drive most of reishi's immune-modulating effects, including stimulation of natural killer cells and macrophages. They do not directly affect CYP enzymes but may contribute to blood pressure changes via cytokine-mediated vascular effects.
• Adenosine and platelet inhibitors. Reishi contains adenosine and other compounds that inhibit platelet aggregation, a property relevant if you also take aspirin or anticoagulants alongside losartan.

The Two Main Interaction Mechanisms You Need to Understand

Mechanism 1: Pharmacokinetic. Reishi May Slow the Activation of Losartan

Because E-3174 forms via CYP2C9, anything that inhibits CYP2C9 reduces the amount of active metabolite available. If reishi's ganoderic acids inhibit CYP2C9 in vivo as they do in liver microsomes, you could theoretically end up with more unmetabolized losartan and less E-3174. The practical consequence is uncertain: losartan itself still has some ARB activity, so blood pressure control might not collapse, but the dose-response curve could shift unpredictably.

This is not a confirmed clinical drug interaction in the way that fluconazole-plus-losartan is confirmed. Fluconazole, a potent CYP2C9 inhibitor, raises losartan area under the curve (AUC) by approximately 50 percent and lowers E-3174 AUC by 47 percent according to pharmacokinetic data reviewed by the FDA. Reishi is almost certainly a weaker inhibitor than fluconazole, but the direction of the effect is the same.

No published human pharmacokinetic study has measured losartan and E-3174 plasma levels before and after adding reishi supplementation. This is a genuine evidence gap, and you deserve to know it exists.

Mechanism 2: Pharmacodynamic. Additive Blood Pressure Lowering

Reishi has blood-pressure-lowering properties in its own right. A small randomized trial involving 26 participants with mild hypertension found that Ganoderma lucidum extract at 1.44 g per day produced a statistically significant reduction in systolic blood pressure compared with placebo over 12 weeks, with a mean decrease of approximately 6.3 mmHg systolic. Adding that effect on top of losartan's own antihypertensive action could produce meaningful hypotension in some women, especially those who are already well-controlled on a moderate dose of losartan.

Signs of additive hypotension to watch for include dizziness on standing (orthostatic hypotension), lightheadedness, palpitations, and fainting. Older postmenopausal women with already-controlled blood pressure are at highest risk for this pharmacodynamic interaction.

Anticoagulant and Bleeding Risk: A Third Concern for Some Women

This concern does not apply to everyone on losartan, but it applies to a meaningful subset. Reishi's platelet-inhibiting compounds act by reducing platelet aggregation, probably through adenosine-receptor pathways and thromboxane inhibition, as shown in preclinical studies published in Blood Coagulation and Fibrinolysis.

If you take losartan alongside aspirin (common in women with cardiovascular disease), warfarin, heparin, or a newer direct oral anticoagulant, adding reishi creates a triple-layer platelet/clotting risk that could raise your bleeding risk meaningfully. This is not a theoretical concern. The Natural Medicines Comprehensive Database rates the combination of reishi with anticoagulant or antiplatelet drugs as a "moderate" interaction warranting clinical supervision.

For women with PCOS who are on low-dose aspirin for pregnancy planning or cardiovascular protection, this is worth a specific conversation with your prescriber.

Pregnancy, Lactation, and Contraception: Read This Section Carefully

Losartan in pregnancy is contraindicated. This is not optional guidance. Losartan carries FDA Pregnancy Category D for the second and third trimesters. When given during the second or third trimester, ARBs can cause fetal renal dysplasia, oligohydramnios, neonatal anuria, skull hypoplasia, limb contractures, and fetal death. Even first-trimester exposure is associated with an elevated risk of congenital malformations in observational cohort data, though the signal is less definitive than for later trimester exposure.

If you are on losartan and could become pregnant, you must use effective contraception. This means a method with a failure rate below 1 percent per year: combined oral contraceptives, a progesterone IUD, a copper IUD, an implant, or a tubal ligation. Condom-only contraception is not adequate when the drug in question causes fetal harm.

If you discover you are pregnant while on losartan, contact your prescriber immediately. Losartan should be switched to a pregnancy-compatible antihypertensive, most commonly labetalol, nifedipine, or methyldopa, as soon as possible.

Reishi mushroom in pregnancy. There is no published safety data from controlled human studies. Animal reproductive toxicology data are sparse. Because the risk is unknown and because some reishi extracts contain polysaccharides that stimulate immune activation, most clinicians advise avoiding reishi entirely during pregnancy. The same precaution applies to preconception supplementation in women undergoing fertility treatment, given the absence of safety data.

Losartan in lactation. Losartan transfers into breast milk in animal models. Human lactation data are absent. The FDA label advises against use during breastfeeding. Alternative antihypertensives with established lactation safety data (such as nifedipine or enalapril) are preferred in nursing mothers.

Reishi in lactation. No human lactation pharmacokinetic data exist. Until safety is established, reishi should not be used by breastfeeding women.

Who This Is Right For and Who Should Avoid This Combination

The following framework was developed by the WomanRx editorial team to help women categorize their individual risk level for the losartan-reishi combination based on life stage, dose, and concurrent medications.

Lower-Concern Scenario

You are postmenopausal, your blood pressure is well above your target (for example, averaging 155/95 mmHg) on losartan 50 mg daily, you take no anticoagulants or antiplatelet drugs, and you want to try a reishi supplement at a low dose (under 1.5 g dried extract per day). Your blood pressure buffer is wide enough that modest additive hypotension is less likely to cause symptoms. You should still tell your prescriber, get a home blood pressure reading at baseline, and recheck at two and four weeks.

Moderate-Concern Scenario

Your blood pressure is already near target on losartan 50 mg or 100 mg daily. You are perimenopausal with significant vasomotor symptoms that affect your blood pressure readings unpredictably. Adding reishi creates a real risk of episodic hypotension, particularly in the mornings. If you proceed, start at the lowest available reishi dose, measure morning and evening blood pressures for at least four weeks, and set a threshold (such as systolic below 105 mmHg) at which you stop reishi and contact your provider.

Higher-Concern or Avoid Scenario

• You are pregnant or trying to conceive. Stop losartan before conception; avoid reishi throughout pregnancy and preconception unless directed otherwise.
• You are breastfeeding. Avoid both in the absence of safety data.
• You take warfarin, a DOAC, or daily aspirin alongside losartan. Adding reishi's platelet-inhibiting effects raises bleeding risk.
• You are a poor CYP2C9 metabolizer. Genetic CYP2C9 poor metabolizer status (approximately 1 to 3 percent of women of European ancestry, with different frequencies in other ancestries) already blunts E-3174 formation. Any further inhibition by reishi could meaningfully impair your losartan response.
• You have known liver disease. Both losartan and reishi are hepatically processed, and liver impairment increases unpredictability for both.

What to Actually Do if You Are Already Taking Both

Many women are already combining reishi and losartan before they find this article. Here is a concrete step-by-step plan:

1. Check your home blood pressure today. Take three readings two minutes apart, sitting quietly, and record the average. Do this morning and evening for three days to establish your current baseline.

2. Tell your prescriber at your next appointment, or message them through your patient portal within one week. Bring the reishi product label so they can see the dose and form (capsule, tincture, or whole mushroom). Dose matters: a 500 mg capsule of dried reishi is not the same as a concentrated 40:1 extract providing ganoderic acid equivalents in the milligram range.

3. Ask whether a basic metabolic panel is warranted. Losartan carries a risk of hyperkalemia (elevated potassium), and some early signals in preclinical literature suggest reishi polysaccharides may have renal effects at high doses. If you have not had kidney function or electrolyte labs in the past six months, now is a reasonable time to check.

4. Watch for these specific symptoms. Lightheadedness when you stand up, unusual fatigue, a pulse below 55 beats per minute at rest, or any unexplained bruising or bleeding warrant prompt contact with your provider.

5. Do not stop losartan abruptly to try reishi instead. Reishi has far less evidence for sustained blood pressure control than losartan. Stopping an ARB without a transition plan can cause rebound hypertension.

What the Evidence Gap Actually Means for You

Women have been historically under-represented in pharmacokinetic drug-interaction studies. The trials that characterize CYP2C9 inhibition tend to use male volunteers or mixed-sex groups that are not powered to detect sex-specific differences. The preclinical reishi-CYP2C9 data come from human liver microsome assays that do not account for cyclical hormonal variation in CYP2C9 activity, which is a real and measurable variable in premenopausal women.

The 2021 Cochrane review on Ganoderma lucidum for hypertension concluded that existing randomized trial data are too limited in sample size and duration to make firm efficacy recommendations. Critically, no trial in that review enrolled patients who were also on antihypertensive medications, which is the exact clinical scenario most women reading this article face.

The honest answer is: the interaction between reishi and losartan is biologically plausible and partially supported by in-vitro data, but the magnitude in living women has not been measured directly. Until it is, clinical caution is the only defensible recommendation.

As Dr. Maya Okafor, MD, WomanRx medical reviewer, notes: "The gap between promising in-vitro CYP inhibition data and a confirmed clinical drug interaction is significant. For women on losartan, the absence of human pharmacokinetic data on this combination is a reason for caution and monitoring, not a reason for alarm. Start low with any new supplement, track your blood pressure, and keep your prescriber in the loop."

Monitoring Plan: A Practical Table

| Time point | What to check | Threshold to act | |---|---|---| | Before starting reishi | Home BP x 3 days, morning and evening | Establish baseline | | Week 1 to 2 | Daily home BP | Systolic <105 or drop >15 mmHg from baseline: stop reishi, call provider | | Week 4 | Home BP + any new symptoms | Same thresholds above | | 3 months | Basic metabolic panel (if not recent) | Potassium >5.5 mEq/L: call provider | | Ongoing | Any dizziness, bruising, unusual fatigue | Prompt provider contact |

Other Supplements That Interact With Losartan Women Should Know About

Since you are already thinking about this category of interaction, a short list of other common supplements that can interact with losartan is worth having:

• Potassium supplements or high-dose potassium salts. Losartan already raises potassium by blocking angiotensin II. Adding potassium supplementation without lab monitoring risks dangerous hyperkalemia, especially in women with mild kidney impairment.
• St. John's Wort. A potent CYP3A4 and P-glycoprotein inducer; can lower losartan blood levels and reduce blood pressure control. This is a confirmed pharmacokinetic interaction.
• Licorice root. Raises blood pressure through aldosterone-like activity and can directly counteract losartan's effect. Particularly relevant for women using licorice-containing "adrenal support" supplements.
• Black cohosh. Commonly used for menopausal symptoms and metabolized partly via CYP2C9. In theory it could compete with losartan's metabolic pathway, though direct interaction data are absent.